In December 2014 the company signed an agreement with Opus Bio, Inc for a chimeric antigen receptor cell product candidate targeting CD22. In April 2015 the company entered into a collaboration with MedImmune investigating combination treatments for cancer. The trials will assess combinations of MEDI4736 and one of Juno's CD19 directed chimeric antigen receptor T cell candidates. In May 2015, the company announced its intention to acquire Stage Cell Therapeutics for up to $223 million. Later in the same month the company launched a collaboration, with Editas Medicine, to create CAR-T and high-affinity T cell receptor therapies to treat cancer, with the potential to generate up to $737 million-plus for Editas. In June, the company acquired X-Body for more than $44 million. In June, the company announced a 10-year partnership with Celgene valued at $1 billion. As part of the deal Celgene will pay Juno $150 million and acquire 9.1 million new Juno shares. Celgene will gain the right to sell Juno's therapies around the world. This partnership surpasses the previous highest record when Pfizer agreed to a deal with Merck KGaA in 2014. In January 2016 Juno announced it had acquired AbVitro, allowing it to use next-generation single cell sequencing platforms to complement its ability to create T cells engineered to target a broad array of cancer targets. Later in July of the same year, the company announced it would acquire RedoxTherapies for $10 million. This acquisition provides Juno with an exclusive license to vipadenant, a small molecule adenosine A2a receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers. In August the company announced it would license rights from Memorial Sloan Kettering Cancer Center and Eureka Therapeutics for a novel, fully human binding domain targeting B-cell maturation antigen. In January 2018, Celgene announced it would acquire Juno for $9 billion.
Lisocabtagene Maraleucel, the company’s autologous anti-CD19 chimeric antigen receptor T-cell immunotherapy with a defined composition of purified CD8+ and CD4+ CAR T cells for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after at least two prior therapies.
